Biotech / Pharma
OMass
Biotech / Pharma
MedCity News reports that Startup OMass secured $310M to advance a drug for a rare endocrine disorder (melanocortin-2 / MC2 for congenital adrenal hyperplasia, per the URL).
Founded
Region
Investors
People